BioCentury | Dec 21, 2018
Financial News

Erasca launches to target cancer drivers

...Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti for $195 million up front. Bionomics Ltd....
BioCentury | Dec 18, 2018
Financial News

Erasca launches to target cancer drivers

...Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti for $195 million up front. Bionomics Ltd....
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

...μM, respectively. Next steps could include testing the compound in animal models of those cancers. Bionomics Ltd....
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...for myeloproliferative disorder. Novartis AG has LGK974 in Phase I testing for Wnt ligand-dependent cancers. Bionomics Ltd....
BioCentury | Oct 5, 2018
Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

...of BNC210. BNC210 is a negative allosteric modulator of nicotinic acetylcholine receptor α 7 (CHRNA7). Bionomics...
...2014. BNC375 is a positive allosteric modulator (PAM) of CHRNA7 (see “Merck, Bionomics Deal” ). Bionomics Ltd....
...clusters, anxiety and depression measures, sleep and safety Status: Development discontinued Milestone: NA Jaime De Leon BNC210, IW-2143 BNC375 Bionomics Ltd. Merck...
BioCentury | Feb 16, 2018
Clinical News

Merck halts Phase III trial of AD candidate verubecestat

...develop and commercialize a preclinical anti-microtubule-associated protein tau (tau; MAPT; FTDP-17) antibody. Also last year, Bionomics Ltd....
...ASX:BNO; OTCQX:BNOEF) received a $10 million milestone payment from Merck under a 2014 deal after Bionomics...
...MCI) and cerebrospinal fluid (CSF) total tau Status: Phase III discontinued Milestone: NA Jaime De Leon MK-8931 SCH 900931 Bionomics Ltd. Merck...
BioCentury | Feb 14, 2018
Clinical News

Merck halts Phase III trial of AD candidate

...develop and commercialize a preclinical anti-microtubule-associated protein tau (tau; MAPT; FTDP-17) antibody. Also last year, Bionomics Ltd....
...ASX:BNO; OTCQX:BNOEF) received a $10 million milestone payment from Merck under a 2014 deal after Bionomics...
...a clinical trial of an undisclosed candidate for cognitive dysfunction associated with AD. Jaime De Leon MK-8931 SCH 900931 verubecestat Bionomics Ltd. Merck...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...stem cell marker leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; GPR49) Acquired in 2012 by Bionomics Ltd....
BioCentury | Apr 18, 2017
Distillery Techniques

Disease models

...using the model to investigate how the intestines contribute to the plasticity of colorectal CSCs. Bionomics Ltd....
BioCentury | Feb 16, 2017
Company News

Bionomics, Merck deal

...Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and other CNS conditions. Bionomics...
...Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Neurology Nora Weintraub BNC375 Bionomics Ltd. Merck...
Items per page:
1 - 10 of 123
BioCentury | Dec 21, 2018
Financial News

Erasca launches to target cancer drivers

...Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti for $195 million up front. Bionomics Ltd....
BioCentury | Dec 18, 2018
Financial News

Erasca launches to target cancer drivers

...Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti for $195 million up front. Bionomics Ltd....
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

...μM, respectively. Next steps could include testing the compound in animal models of those cancers. Bionomics Ltd....
BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

...for myeloproliferative disorder. Novartis AG has LGK974 in Phase I testing for Wnt ligand-dependent cancers. Bionomics Ltd....
BioCentury | Oct 5, 2018
Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

...of BNC210. BNC210 is a negative allosteric modulator of nicotinic acetylcholine receptor α 7 (CHRNA7). Bionomics...
...2014. BNC375 is a positive allosteric modulator (PAM) of CHRNA7 (see “Merck, Bionomics Deal” ). Bionomics Ltd....
...clusters, anxiety and depression measures, sleep and safety Status: Development discontinued Milestone: NA Jaime De Leon BNC210, IW-2143 BNC375 Bionomics Ltd. Merck...
BioCentury | Feb 16, 2018
Clinical News

Merck halts Phase III trial of AD candidate verubecestat

...develop and commercialize a preclinical anti-microtubule-associated protein tau (tau; MAPT; FTDP-17) antibody. Also last year, Bionomics Ltd....
...ASX:BNO; OTCQX:BNOEF) received a $10 million milestone payment from Merck under a 2014 deal after Bionomics...
...MCI) and cerebrospinal fluid (CSF) total tau Status: Phase III discontinued Milestone: NA Jaime De Leon MK-8931 SCH 900931 Bionomics Ltd. Merck...
BioCentury | Feb 14, 2018
Clinical News

Merck halts Phase III trial of AD candidate

...develop and commercialize a preclinical anti-microtubule-associated protein tau (tau; MAPT; FTDP-17) antibody. Also last year, Bionomics Ltd....
...ASX:BNO; OTCQX:BNOEF) received a $10 million milestone payment from Merck under a 2014 deal after Bionomics...
...a clinical trial of an undisclosed candidate for cognitive dysfunction associated with AD. Jaime De Leon MK-8931 SCH 900931 verubecestat Bionomics Ltd. Merck...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...stem cell marker leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; GPR49) Acquired in 2012 by Bionomics Ltd....
BioCentury | Apr 18, 2017
Distillery Techniques

Disease models

...using the model to investigate how the intestines contribute to the plasticity of colorectal CSCs. Bionomics Ltd....
BioCentury | Feb 16, 2017
Company News

Bionomics, Merck deal

...Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and other CNS conditions. Bionomics...
...Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Neurology Nora Weintraub BNC375 Bionomics Ltd. Merck...
Items per page:
1 - 10 of 123